NCM · Financial Statements

Revelation Biosciences, Inc. (REVB) Revenue, Earnings & Financial Statements

$3.88 NCM: REVB Market Cap $2.21M

Data as of Nov 17, 2026 close · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)

Revelation Biosciences, Inc. most recently reported annual revenue of $0, a net loss of $9.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Revelation Biosciences, Inc.: net profit was positive in 0 of 7 reported years; the most recent year shows a net loss of $9.0M.

Income Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Revenue$0$0$0$0$0$0$0
Operating Expenses$0$4.0M$12.0M$11.0M$9.0M$8.0M$9.0M
Operating Profit$0−$4.0M−$12.0M−$11.0M−$9.0M−$8.0M−$9.0M
Other Income$0$0$0$0$9.0M−$7.0M$0
Interest$0$0$0$0$0$0$0
Depreciation$0$4.0M$0$0$0$0$0
Profit Before Tax$0−$4.0M−$12.0M−$11.0M$0−$15.0M−$9.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit$0−$2.0M−$12.0M−$11.0M$0−$15.0M−$9.0M
EPS−$47.04−$63228.83−$142800.00−$67503.59−$58.87−$613.76−$167.65

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$3.0M$2.0M$2.0M$3.0M$2.0M$2.0M$2.0M$2.0M$2.0M$3.0M$3.0M$4.0M
Operating Profit−$3.0M−$2.0M−$2.0M−$3.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M−$3.0M−$3.0M−$4.0M
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$3.0M−$2.0M−$3.0M−$8.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M−$3.0M−$3.0M−$3.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$3.0M−$2.0M−$3.0M−$8.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M−$3.0M−$3.0M−$3.0M
EPS−$1402.38−$932.68−$275.59−$574.63−$93.66−$34.86−$14.77−$49.07−$12.39−$11.55−$18.97−$6.09

Over the 7 years reported for Revelation Biosciences, Inc., cash stood at $11.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 5.50 times.

Balance Sheet — 7 Years (USD millions)

Metric2019202020212022202320242025
Total Assets$0$74.0M$2.0M$6.0M$12.0M$7.0M$12.0M
Current Assets$0$1.0M$2.0M$5.0M$12.0M$7.0M$11.0M
Cash$0$0$1.0M$5.0M$12.0M$6.0M$11.0M
Inventory$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$0
Fixed Assets$0$0$0$0$0$0$1.0M
Capital Work in Progress$0$0$0$0$0$0$0
Investments$0$74.0M$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0
Total Liabilities$0$6.0M$2.0M$4.0M$6.0M$2.0M$3.0M
Current Liabilities$0$3.0M$2.0M$4.0M$6.0M$2.0M$2.0M
Borrowings$0$0$0$0$0$0$1.0M
Other Liabilities$0$6.0M$2.0M$4.0M$6.0M$2.0M$2.0M
Equity$0$74.0M$0$0$0$0$0
Reserves$0$68.0M$0$1.0M$7.0M$5.0M$9.0M

For Revelation Biosciences, Inc., operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $8.0M; free cash flow was positive in 0 of 7 years.

Cash Flow Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Operating Cash Flow$0$0−$11.0M−$11.0M−$7.0M−$18.0M−$8.0M
Investing Cash Flow$0−$74.0M$0$0$0$0$0
Financing Cash Flow$0$0$0$12.0M$0$0$0
Net Cash Flow$0$0−$3.0M$4.0M$7.0M−$5.0M$4.0M
Free Cash Flow$0$0−$11.0M−$11.0M−$7.0M−$18.0M−$8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.75
FCF Yield-374.44%
Quick Ratio6.21
Interest Coverage—
Return 1Y9.85%
Return 3Y-99.89%
Return 5Y-100.00%

Revelation Biosciences, Inc. (REVB) financials — frequently asked questions

What is Revelation Biosciences, Inc.'s annual revenue?

Revelation Biosciences, Inc. (REVB) reported annual revenue of $0 in its most recent fiscal year.

What is Revelation Biosciences, Inc.'s net profit?

Revelation Biosciences, Inc. (REVB) reported a net loss of $9.0M in its most recent fiscal year.

What is REVB EV/EBITDA?

Revelation Biosciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 0.75.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
REVB Overview REVB Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.